[go: up one dir, main page]

IL316911A - Stabilized HMPV prefusion proteins - Google Patents

Stabilized HMPV prefusion proteins

Info

Publication number
IL316911A
IL316911A IL316911A IL31691124A IL316911A IL 316911 A IL316911 A IL 316911A IL 316911 A IL316911 A IL 316911A IL 31691124 A IL31691124 A IL 31691124A IL 316911 A IL316911 A IL 316911A
Authority
IL
Israel
Prior art keywords
fusion
hmpv
stabilized pre
fusion proteins
proteins
Prior art date
Application number
IL316911A
Other languages
English (en)
Hebrew (he)
Original Assignee
Msd Int Business Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Int Business Gmbh filed Critical Msd Int Business Gmbh
Publication of IL316911A publication Critical patent/IL316911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL316911A 2022-05-12 2023-05-11 Stabilized HMPV prefusion proteins IL316911A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (1)

Publication Number Publication Date
IL316911A true IL316911A (en) 2025-01-01

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316911A IL316911A (en) 2022-05-12 2023-05-11 Stabilized HMPV prefusion proteins

Country Status (15)

Country Link
EP (1) EP4522209A1 (es)
JP (1) JP2025521082A (es)
KR (1) KR20250010642A (es)
CN (1) CN119562826A (es)
AU (1) AU2023269241A1 (es)
CA (1) CA3253332A1 (es)
CL (1) CL2024003418A1 (es)
CO (1) CO2024015386A2 (es)
CR (1) CR20240493A (es)
DO (1) DOP2024000230A (es)
GE (1) GEAP202516650A (es)
IL (1) IL316911A (es)
MX (1) MX2024013959A (es)
PE (1) PE20251395A1 (es)
WO (1) WO2023217988A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436325A (zh) 2023-01-18 2024-09-16 美商輝瑞大藥廠 針對呼吸道疾病之疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
US20260021175A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
IL321500A (en) * 2020-10-09 2025-08-01 Univ Texas Pre-stabilized hmpv f proteins

Also Published As

Publication number Publication date
EP4522209A1 (en) 2025-03-19
KR20250010642A (ko) 2025-01-21
PE20251395A1 (es) 2025-05-22
AU2023269241A1 (en) 2024-11-21
CR20240493A (es) 2025-01-29
JP2025521082A (ja) 2025-07-08
CA3253332A1 (en) 2023-11-16
MX2024013959A (es) 2025-02-10
DOP2024000230A (es) 2025-02-16
CL2024003418A1 (es) 2025-08-01
WO2023217988A1 (en) 2023-11-16
GEAP202516650A (en) 2025-03-10
CO2024015386A2 (es) 2024-11-28
CN119562826A (zh) 2025-03-04

Similar Documents

Publication Publication Date Title
IL316911A (en) Stabilized HMPV prefusion proteins
IL282892A (en) Pre-fusion RSV F proteins are stabilized
IL289887A (en) A fusion polypeptide for immunotherapy
EP3755726A4 (en) Fusion proteins for base editing
SG11202107454UA (en) Multi-functional fusion proteins and uses thereof
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
IL275691A (en) Antibody-fused proteins with a single-site cytosine daminase
IL290675A (en) Medical protein concentrates
GB202005879D0 (en) Heterodimeric proteins
IL324680A (en) Relaxin-2 fusion protein analogs and methods of using them
GB202113559D0 (en) Fusion polypeptide
IL299238A (en) ANTI-PD-1 antibodies and fusion proteins
GB202003611D0 (en) Stabilised viral fusion proteins
HK40119896A (en) Stabilized pre-fusion hmpv fusion proteins
IL291618A (en) Heterodimeric proteins
GB202307936D0 (en) Fusion protein
GB202307932D0 (en) Fusion protein
EP4165066A4 (en) FUSION POLYPEPTIDE
GB202105044D0 (en) Fusion protein
EP3503911A4 (en) COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME
IL317593A (en) Follistatin-FC fusion proteins
GB202218084D0 (en) Fusion proteins
HK40108514A (en) Stabilized pre-fusion piv3 f proteins
EP4100444A4 (en) MUCIN-BINDING FUSION PROTEINS
HK40127199A (zh) 稳定的融合前piv3f蛋白